Incidence, predictors, and clinical outcomes of new-onset diabetes mellitus after percutaneous coronary intervention with drug-eluting stent

Kyeong Hyeon Chun, Eui Im, Byeong Keuk Kim, Dong Ho Shin, Jung Sun Kim, Young Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong Ki Hong

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We investigated the incidence, predictors, and long-term clinical outcomes of new-onset diabetes mellitus (DM) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). A total of 6,048 patients treated with DES were retrospectively reviewed and divided into three groups: 1) known DM (n = 2,365; fasting glucose ≥ 126 mg/dL, glycated hemoglobin ≥ 6.5%, already receiving DM treatment, or previous history of DM at the time of PCI); 2) non-DM (n = 3,247; no history of DM, no laboratory findings suggestive of DM at PCI, and no occurrence of DM during follow-up); and 3) new-onset DM (n = 436; non-DM features at PCI and occurrence of DM during follow-up). Among 3,683 non-DM patients, 436 (11.8%) patients were diagnosed with new-onset DM at 3.4 ± 1.9 years after PCI. Independent predictors for new-onset DM were high-intensity statin therapy, high body mass index (BMI), and high level of fasting glucose and triglycerides. The 8-year cumulative rate of major adverse cardiac events (a composite of cardiovascular death, myocardial infarction, stent thrombosis, or any revascularization) in the new-onset DM group was 19.5%, which was similar to 20.5% in the non-DM group (P = 0.467), but lower than 25.0% in the known DM group (P = 0.003). In conclusion, the incidence of new-onset DM after PCI with DES was not low. High-intensity statin therapy, high BMI, and high level of fasting glucose and triglycerides were independent predictors for new-onset DM. Long-term clinical outcomes of patients with new-onset DM after PCI were similar to those of patients without DM.

Original languageEnglish
Pages (from-to)1603-1609
Number of pages7
JournalJournal of Korean medical science
Volume32
Issue number10
DOIs
Publication statusPublished - 2017 Oct 1

Fingerprint

Drug-Eluting Stents
Percutaneous Coronary Intervention
Diabetes Mellitus
Incidence
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Fasting
Glucose
Triglycerides
Body Mass Index
Glycosylated Hemoglobin A

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{a3db20a6ce29478db0a7c0dddc392e97,
title = "Incidence, predictors, and clinical outcomes of new-onset diabetes mellitus after percutaneous coronary intervention with drug-eluting stent",
abstract = "We investigated the incidence, predictors, and long-term clinical outcomes of new-onset diabetes mellitus (DM) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). A total of 6,048 patients treated with DES were retrospectively reviewed and divided into three groups: 1) known DM (n = 2,365; fasting glucose ≥ 126 mg/dL, glycated hemoglobin ≥ 6.5{\%}, already receiving DM treatment, or previous history of DM at the time of PCI); 2) non-DM (n = 3,247; no history of DM, no laboratory findings suggestive of DM at PCI, and no occurrence of DM during follow-up); and 3) new-onset DM (n = 436; non-DM features at PCI and occurrence of DM during follow-up). Among 3,683 non-DM patients, 436 (11.8{\%}) patients were diagnosed with new-onset DM at 3.4 ± 1.9 years after PCI. Independent predictors for new-onset DM were high-intensity statin therapy, high body mass index (BMI), and high level of fasting glucose and triglycerides. The 8-year cumulative rate of major adverse cardiac events (a composite of cardiovascular death, myocardial infarction, stent thrombosis, or any revascularization) in the new-onset DM group was 19.5{\%}, which was similar to 20.5{\%} in the non-DM group (P = 0.467), but lower than 25.0{\%} in the known DM group (P = 0.003). In conclusion, the incidence of new-onset DM after PCI with DES was not low. High-intensity statin therapy, high BMI, and high level of fasting glucose and triglycerides were independent predictors for new-onset DM. Long-term clinical outcomes of patients with new-onset DM after PCI were similar to those of patients without DM.",
author = "Chun, {Kyeong Hyeon} and Eui Im and Kim, {Byeong Keuk} and Shin, {Dong Ho} and Kim, {Jung Sun} and Ko, {Young Guk} and Donghoon Choi and Yangsoo Jang and Hong, {Myeong Ki}",
year = "2017",
month = "10",
day = "1",
doi = "10.3346/jkms.2017.32.10.1603",
language = "English",
volume = "32",
pages = "1603--1609",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "10",

}

Incidence, predictors, and clinical outcomes of new-onset diabetes mellitus after percutaneous coronary intervention with drug-eluting stent. / Chun, Kyeong Hyeon; Im, Eui; Kim, Byeong Keuk; Shin, Dong Ho; Kim, Jung Sun; Ko, Young Guk; Choi, Donghoon; Jang, Yangsoo; Hong, Myeong Ki.

In: Journal of Korean medical science, Vol. 32, No. 10, 01.10.2017, p. 1603-1609.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Incidence, predictors, and clinical outcomes of new-onset diabetes mellitus after percutaneous coronary intervention with drug-eluting stent

AU - Chun, Kyeong Hyeon

AU - Im, Eui

AU - Kim, Byeong Keuk

AU - Shin, Dong Ho

AU - Kim, Jung Sun

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Hong, Myeong Ki

PY - 2017/10/1

Y1 - 2017/10/1

N2 - We investigated the incidence, predictors, and long-term clinical outcomes of new-onset diabetes mellitus (DM) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). A total of 6,048 patients treated with DES were retrospectively reviewed and divided into three groups: 1) known DM (n = 2,365; fasting glucose ≥ 126 mg/dL, glycated hemoglobin ≥ 6.5%, already receiving DM treatment, or previous history of DM at the time of PCI); 2) non-DM (n = 3,247; no history of DM, no laboratory findings suggestive of DM at PCI, and no occurrence of DM during follow-up); and 3) new-onset DM (n = 436; non-DM features at PCI and occurrence of DM during follow-up). Among 3,683 non-DM patients, 436 (11.8%) patients were diagnosed with new-onset DM at 3.4 ± 1.9 years after PCI. Independent predictors for new-onset DM were high-intensity statin therapy, high body mass index (BMI), and high level of fasting glucose and triglycerides. The 8-year cumulative rate of major adverse cardiac events (a composite of cardiovascular death, myocardial infarction, stent thrombosis, or any revascularization) in the new-onset DM group was 19.5%, which was similar to 20.5% in the non-DM group (P = 0.467), but lower than 25.0% in the known DM group (P = 0.003). In conclusion, the incidence of new-onset DM after PCI with DES was not low. High-intensity statin therapy, high BMI, and high level of fasting glucose and triglycerides were independent predictors for new-onset DM. Long-term clinical outcomes of patients with new-onset DM after PCI were similar to those of patients without DM.

AB - We investigated the incidence, predictors, and long-term clinical outcomes of new-onset diabetes mellitus (DM) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). A total of 6,048 patients treated with DES were retrospectively reviewed and divided into three groups: 1) known DM (n = 2,365; fasting glucose ≥ 126 mg/dL, glycated hemoglobin ≥ 6.5%, already receiving DM treatment, or previous history of DM at the time of PCI); 2) non-DM (n = 3,247; no history of DM, no laboratory findings suggestive of DM at PCI, and no occurrence of DM during follow-up); and 3) new-onset DM (n = 436; non-DM features at PCI and occurrence of DM during follow-up). Among 3,683 non-DM patients, 436 (11.8%) patients were diagnosed with new-onset DM at 3.4 ± 1.9 years after PCI. Independent predictors for new-onset DM were high-intensity statin therapy, high body mass index (BMI), and high level of fasting glucose and triglycerides. The 8-year cumulative rate of major adverse cardiac events (a composite of cardiovascular death, myocardial infarction, stent thrombosis, or any revascularization) in the new-onset DM group was 19.5%, which was similar to 20.5% in the non-DM group (P = 0.467), but lower than 25.0% in the known DM group (P = 0.003). In conclusion, the incidence of new-onset DM after PCI with DES was not low. High-intensity statin therapy, high BMI, and high level of fasting glucose and triglycerides were independent predictors for new-onset DM. Long-term clinical outcomes of patients with new-onset DM after PCI were similar to those of patients without DM.

UR - http://www.scopus.com/inward/record.url?scp=85029129414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029129414&partnerID=8YFLogxK

U2 - 10.3346/jkms.2017.32.10.1603

DO - 10.3346/jkms.2017.32.10.1603

M3 - Article

C2 - 28875603

AN - SCOPUS:85029129414

VL - 32

SP - 1603

EP - 1609

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 10

ER -